Search

Displaying results 7101 - 7110 of 8696 in total
  1. Drug

    Thymectacin

    go.drugbank.com/drugs/DB05116
    Investigational

    Thymectacin was as efficacious as irinotecan, a drug recently approved for the treatment of 5-fluorouracil-resistant colon cancer.

  2. Drug

    Col-118

    go.drugbank.com/drugs/DB05778
    Investigational

    COL-118, a topical compound based on the SansRosa technology, for the treatment of redness associated with rosacea and other skin disorders. … Col-118 is a unique formulation and presentation of Brimonidine, which is a selective alpha-2 adrenergic receptor agonist.

  3. Drug

    Halofuginone

    go.drugbank.com/drugs/DB04866
    InvestigationalVet approved

    Collgard Biopharmaceuticals is developing halofuginone for the treatment of scleroderma and received orphan drug designation from the U.S. Food and Drug Administration in March, 2000.

  4. Drug

    Pristinamycin

    go.drugbank.com/drugs/DB13704
    Investigational

    Categories: Antibacterials for Systemic Use, Antiinfectives for Systemic Use
  5. Drug

    LIS-1

    go.drugbank.com/drugs/DB18388
    Experimental

    LIS-1 is an immunoglobulin G (IgG) polyclonal antibody that binds to human T cells.

  6. Drug

    RGG0853

    go.drugbank.com/drugs/DB18669
    Experimental

    RGG0853 is an E1A lipid complex, a repressor gene complexed with a cationic lipid vector.

    Synonyms: HER-2/neu inhibitor
  7. Drug

    Ammonium trichlorotellurate

    go.drugbank.com/drugs/DB17740
    Investigational

    Ammonium trichlorotellurate is an investigational compound with anti-tumour [A259147] and anti-inflammatory properties.[A259152]

  8. Drug

    BMN-351

    go.drugbank.com/drugs/DB18186
    Investigational

    It is under investigation for the treatment of Duchenne Muscular Dystrophy (DMD).

  9. Drug

    Insulin efsitora alfa

    go.drugbank.com/drugs/DB19013
    Investigational

    alfa is under investigation in clinical trial NCT05662332 (A Study of Insulin Efsitora Alfa (LY3209590) Compared to Glargine in Adult Participants With Type 2 Diabetes Who Are Starting Basal Insulin for

  10. Drug

    CEP-1347

    go.drugbank.com/drugs/DB05403
    Investigational

    CEP-1347 is a semi-synthetic compound shown to protect multiple nerve cell types from a variety of insults leading to programmed cell death (apoptosis) which could improve the survival of dopamine neurons prior to and after transplantation.